Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Publishing timestamp: 2023-04-25 13:56:40
Summary
Biogen CEO Christopher Viehbacher said that the company is not worried about competing with Eli Lilly as they both try to roll out drugs to treat early stages of Alzheimer's disease. Viehbacher said that Eli Lilly's decision to stop dosing drug after it clears certain amount of toxic amyloid brain plaque in patient may not be the best approach. Biogen and Eisai expect the Food and Drug Administration to grant full approval of leqembi by summer, and the companies are already preparing to apply for approval of maintenance doses by the first quarter of 2024. Eli Lilly is developing donanemab and another drug, remternetug, after the company's older treatment, solanezumab, failed to slow the progression of Alzheimer's in clinical trials.
Sentiment: NEUTRAL
Tickers: ESALY, BIIB, 4523.T-JP, LLY,
Keywords: biotech and pharmaceuticals, business, pharmaceuticals, health care industry, breaking news, business news, alzheimer's disease, science, breaking news: business, eli lilly and co, biogen inc, biotechnology, eisai co ltd,
Source: https://www.cnbc.com/2023/04/25/biogen-alzheimers-competition-eli-lilly.html